Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Living Cell Technologies Granted European Patent

Living Cell Technologies Limited

 
Living Cell Technologies Granted European Patent for Neurological Disease Product NTCELL

NTCELL targets neurological diseases such as Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis and Huntington’s disease and Stroke
Patent based on technology of implanting encapsulated porcine choroid plexus cells
Journal of Neural Engineering publishes LCT’s latest data on therapeutic benefit of choroid plexus cell implants

20 January 2010: Sydney, Australia, Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that it has been granted a European patent for the use of its product NTCELL in the treatment of degenerative neurological conditions such as Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis (MS), Huntington’s disease and Stroke.

LCT’s European patent is based on the technology of preparing NTCELL, which are encapsulated porcine cells of the choroid plexus of the brain. The cells release growth factors and neurotrophins, which are a range of agents that protect and maintain the health of brain cells. NTCELL was designed to protect brain cells from disease and injury and to enhance the natural repair mechanisms in the brain. NTCELL has the potential to restore neural cells and tissue.

The porcine choroid plexus cells are encapsulated in a seaweed-derived gel. The encapsulation protects the cells from rejection by the immune system allowing implantation without the need for toxic anti-rejection drugs.

Dr Paul Tan, Chief Executive Officer LCT said: “At a time when we are seeing regulatory approvals in Europe and the US for clinical trials with cell-based therapeutics in neurologic disorders, we can expect NTCELL to add significant value to LCT. The granting of this key patent for NTCELL coincides with the publication of LCT’s most recent data on cell therapy for neurological diseases in a leading peer review journal.”

The December 2009 issue of the Journal of Neural Engineering published LCT’s paper titled “Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma”, which shows that long-lasting therapeutic implants of NTCELL may be used to treat brain disease. The new experimental data indicates that the choroid plexus cells release neuroprotective agents including antioxidants and growth supporting factors. The implanted cells were still alive when retrieved 6 months after implantation into the brain in animals. This publication adds to LCT’s previously published and presented data on the beneficial effects of NTCELL implants in animal models of Parkinson’s disease, Huntington’s disease, stroke and hearing loss caused by degeneration of the auditory nerve.

 

-Ends-

 

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Prefu Roundup: Forecasts Revised, Surplus Intact

The National government heads into the election with its Budget surplus target broadly intact, delivering a set of economic and fiscal forecasts marginally revised from May to reflect weaker commodity prices and a lower tax take. More>>

ALSO:

Convention Centre: Major New SkyCity Hotel And Laneway For Auckland

Today SKYCITY Entertainment Group Limited revealed plans to build a new hotel and pedestrian laneway of bars, restaurants and boutique shopping on land it owns in the Nelson and Hobson Streets block, expanding the SKYCITY Entertainment Precinct. More>>

ALSO:

Igniting The Spark: Bringing The Digital Enabler To Life

Changing a name is, relatively speaking, the easy part of a re-invention. Changing a culture, getting all the ducks in a row, turning yourself inside-out to become customer-inspired is a much bigger challenge. More>>

ALSO:

Ebola And NZ: Targeted Screening At Airport But Risk Low

The risk of any cases of Ebola in New Zealand remains very low, but health and border authorities are well prepared... anyone arriving in New Zealand who in the last three weeks has visited countries affected will be screened for symptoms of the disease. More>>

ALSO:

Scoop Business: Brewer Seeking Crowd-Funding Cancels Shareholders’ Dividends

Shareholders in Renaissance Brewing company, the first business to seek equity through crowd-funding in New Zealand, have cancelled their claim on $147,000 of accumulated earnings “to make Renaissance a more attractive investment opportunity.” More>>

ALSO:

It's Spark Now:
Why Telecom Wanted To Change

New Zealand led the world when Chorus demerged from Telecom. It gave us a telecommunications industry structure where the network is completely separated from the products and services it delivers. The changes brought about a new market dynamic and it dramatically changed Telecom’s role. More>>

ALSO:

Glass Half Empty: Dairy Prices Fall To Lowest Since 2012

Dairy product prices slumped to the lowest level since October 2012 in the latest GlobalDairyTrade auction, paced by whole milk powder and cheddar. More>>

ALSO:

Get More From Scoop

 
 
Computer Power Plus

Standards New Zealand

Standards New Zealand
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news